Meningococcal vaccines: a progress report.
Neisseria meningitidis causes a wide range of human disease and remains a common cause of septicaemia and meningitis. Meningococcal serogroups A, B, C and Y cause the majority of cases of invasive disease in the US and throughout the world, with epidemics usually caused by serogroups A and C. Most patients with meningococcaemia, with or without meningitis, respond to standard antimicrobial therapy with either penicillin or ampicillin, but the recent emergence of meningococcal strains that are intermediately resistant to penicillin may alter these recommendations in the future. Given the devastating nature of meningococcal disease and emergence of these resistant strains, prevention (specifically through vaccination) remains the best approach to control this serious infection. A polysaccharide meningococcal vaccine is efficacious against disease caused by serogroups A, C, Y and W135, but is not effective in infants and children aged <2 years, and the duration of efficacy decreases markedly during the first 3 years after a single dose of the vaccine. Conjugate meningococcal vaccines have been developed to address these concerns. Initial studies with the meningococcal C conjugate vaccine have shown that the vaccine is safe and immunogenic and provides a T cell-dependent antigen that can be boosted by further doses of vaccine, or following exposure to the homologous organism or cross-reacting antigens. The UK recently implemented routine vaccination with the meningococcal C conjugate vaccine to all infants, and to all persons aged >1 year in a catch-up programme to immunise all school-aged children and young adults up to 20 years of age. Early postlicensure data indicate that this vaccine has shown significant efficacy in reduction of invasive meningococcal disease in these age groups. The full impact of vaccination will be determined once all age groups are immunised.
Wildes
Simone S
SS
Division of Infectious Diseases, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Tunkel
Allan R
AR
D000818:Animals; D006801:Humans; D008585:Meningitis, Meningococcal / Q000097:blood / Q000188:drug therapy / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000097:blood / Q000627:therapeutic use*; D009345:Neisseria meningitidis / Q000276:immunology*; D016730:Program Development / Q000706:statistics & numerical data
D022401:Meningococcal Vaccines